Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.
Hi, everyone. Tony Sri from GNA Farber Cancer Institute. Um uh It was wonderful uh to have uh EO 24 again in uh Chicago, I was pleased to be senior author on in phase three trial. Uh The latest, latest final overall survival analysis from Jav and Renald 101, which established uh the combination of the PDL one inhibitor, Avila plus exit as a standard first line therapy based on progression free survival. Here, we had over 68 months follow up including the final analysis for uh overall survival. And despite there was a numerical difference both in the primary end point in PDL one positive as well as in the overall population, a secondary endpoint in numerical difference, favoring overall survival with the combination uh compared to single agent that um difference did not reach a statistical significance, progression free survival. Overall response rate remained statistic significant benefiting the combination and uh the long term safety profile of exit and Plavi was consistent actually with previous analysis. Great meeting ES 0 2024 was a lot of uh showcase from my colleagues at the Dana Farmer
